In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.VISIT NEW SITE
Digestive health supplement lifts Immuron’s sales
2 minute read
Immuron Limited (ASX:IMC | NASDAQ:IMRN) today announced that sales for its commercially available products, including Travelan®, surged by 66% in the third quarter.
Immuron is an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, including Travelan®, its over-the-counter gastrointestinal and digestive health supplement.
Worldwide product sales reached $616,000 in the quarter ending March 31, up from 371,000 in Q3 2018. While sales for the year to date hit $1.7 million, up 23% from this time a year ago.
In Australia, Travelan® sales rocketed to A$332,000 in Q3 FY19, representing a 73% increase over Q3 FY18 (A$192,000) demonstrating that efforts to raise consumer awareness of the brand through expanded co-operative Marketing initiatives with major Pharmacy banners have impacted positively on sales.
Sales for the year to March 31 of Travelan® in Australia exceeded the A$1 million mark and are 18% higher than the same time last year.
In the US, Travelan® sales surged ahead growing 60% YoY to A$266,000 for Q3 2019 as the partnership with USA’s largest travel medicine network, Passport Health continues.
Sales of Travelan® on the Amazon Platform are also steadily increasing. YTD March 31 US Sales (A$635,000) are sitting 27% higher than the same time last year.
Dr Gary S. Jacob, CEO of Immuron, said of the results, “Our concerted focus on expanding sales growth of Travelan® within existing markets, coupled with our re-entry into Canada puts us in a strong position for continued growth.
“We will continue to work towards expanded sales growth, with particular emphasis on building the market for Travelan® in North America.”
Today’s announcement follows news last week that IMC plans to pursue clinical development of IMM-124E, its bovine polyclonal antibody drug candidate to prevent travelers’ diarrhea, through a formal FDA registration pathway.
It also comes after the company's Chemist Warehouse Ad went live on April 12 and wil run through to April 18: